PGR and neoplasm: The most commonly used immunohistochemical prognostic and therapeutic biomarkers include estrogen (ER) and progesterone receptors (PgR), human epidermal growth factor receptor 2 (HER2), and proliferation index (Ki-67) which translates the proliferative and aggressive potential of the tumor.